Kadimastem, an Israeli biotechnology company that develops human pluripotent stem cell-related products, announced the signing of a five year framework agreement with Merck Serono. The agreement concerns the use of Kadimastem’s drug-screening platform to discover new oral drugs for the treatment of the neurological disease Multiple Sclerosis (MS). The company is based in Nes-Ziona, Israel.
Related posts
Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023
Model Sees Daylight As Boost For Hospitalized Patients’ Health
September 28, 2023
Solar Panels On A Roll Certified As Safe For Use In US, Europe
September 28, 2023
US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023
Facebook comments